There's no retail retatrutide cost to quote, because there's no approved product. Research-grade material sells by the vial at roughly $12–$18 per mg, and vial size drives most of the gap between suppliers. A cheap vial can look like a bargain and still tell you nothing about what's inside it.
Retatrutide has no retail price because it has no approval. There is no Zepbound-style list price to quote. Research-grade material is priced by the vial. The only number worth comparing is cost per milligram, at a stated purity and testing standard. Vial size drives most of the apparent price gap between suppliers.
Search “retatrutide price” and you'll find numbers quoted with a confidence the market doesn't support. Here's why. Retatrutide is investigational, so there's no label, no pharmacy channel, no insurance code and no list price.
Everything being quoted is the price of a research chemical, and research chemicals are priced by the vial. That makes headline prices close to meaningless until you normalize them.
Cost per mg is the only comparable number
Retatrutide sells in 5, 10, 15 and 20 mg vials. Those are different amounts of material at different price points, and larger vials nearly always price better per milligram. We'd divide before comparing anything.
| Vial | Illustrative price | Cost per mg | What it means |
|---|---|---|---|
| 5 mg | $90 | $18.00 | Lowest sticker, highest unit cost |
| 10 mg | $150 | $15.00 | The usual reference presentation |
| 15 mg | $200 | $13.33 | Volume discount starts to bite |
| 20 mg | $240 | $12.00 | Best unit economics, most capital at risk on one lot |
Those figures illustrate the shape, not a price list, so check current pricing at source. The point is structural. A supplier can look 40% cheaper on the product page and still be more expensive per milligram.
That's the most common way peptide pricing misleads people. Our full cost-per-mg methodology covers how to run this across a whole catalog.
The cheapest vial on the page is a signal, not a bargain. Peptide synthesis has a real floor cost, and third-party analytical testing adds a fixed charge per lot. It's typically several hundred dollars, spread across however many vials that lot produced.
A supplier pricing dramatically below the market has usually economized on one of those two. Small lots make the testing cost per vial punishing, which is exactly why untested material is cheap.
Why the prescription comparison is not a comparison
Most people reach for retatrutide pricing after seeing what a branded GLP-1 costs, and the gap is enormous. We'd be precise about what that gap represents, because it isn't markup.
A prescription incretin's price carries GMP manufacturing, sterile fill-finish, batch release testing, endotoxin and sterility assurance, and stability programs. It also carries pharmacovigilance, a regulator empowered to force a recall, clinical oversight and product liability.
A research compound carries synthesis, plus third-party analytical testing on the powder if you selected for it. Those are different products at different levels of assurance, and the price difference is what the assurance is worth.
What research-grade actually means unpacks the manufacturing distinction. Our 503A compounding landscape page covers the middle tier between the two.
GLP3-R (retatrutide)
The triple-agonist reference compound used across the Jastreboff Phase 2 literature. Research use only — supplied with a batch-matched certificate of analysis.
What to check before price
Price is the last variable, not the first. Run these four in order, and only compare cost across the suppliers that clear all of them.
- Batch-matched COA. The lot number on the certificate matches the lot number on your vial. A product-line PDF is not a COA for your material.
- Identity, not just purity. Mass spectrometry confirming molecular weight alongside the HPLC trace. Retatrutide is a 39-amino-acid peptide; a similar-looking peak is not proof it is the right one.
- A named lab. “Third-party tested” with no third party named is a marketing phrase.
- Consistent presentation. Lyophilized, sealed, correctly labeled, with stated storage conditions. Storage and stability is where a good lot goes bad in transit.
Our retatrutide sourcing guide covers where to actually source it, and the specific ways the compound gets substituted or underfilled.
Vial price is a packaging decision. Cost per milligram at a stated purity is the only number that compares one supplier to another.
— WTBP Research Team note, 2026
Frequently asked questions
How much does retatrutide cost?
There is no retail price because there is no approved product. Research-grade retatrutide is sold by the vial, typically in 5, 10, 15 and 20 mg presentations, and the only sane way to compare offers is cost per milligram. Anything else is comparing different amounts of material.
Why is research retatrutide so much cheaper than a prescription GLP-1?
Because you are not buying the same thing. A prescription drug price covers GMP manufacturing, sterility assurance, batch release testing, regulatory oversight, clinical support and liability. A research compound covers synthesis and, if you chose well, third-party analytical testing. The price gap is the value of everything the research product does not include.
What is a fair cost per mg for retatrutide?
Work it out rather than trusting a number: divide the vial price by the milligrams in the vial, then compare across suppliers at the same purity and testing standard. Large vials almost always price better per milligram, which is why a cheap-looking 5 mg vial is often the most expensive material on the page.
Does a higher price mean higher quality?
No. Price tracks marketing spend and margin at least as much as it tracks analytical rigor. What correlates with quality is a batch-matched certificate of analysis from a named external lab showing both HPLC purity and mass-spec identity. That's checkable. A price isn't.
What we’re watching
Retatrutide pricing moves when supply does. We're watching whether the TRIUMPH Phase 3 program's raw-material demand pulls research-channel prices up, or whether more contract manufacturers entering pushes the per-mg figure down.
The other thing worth tracking is testing depth. If batch-matched mass-spec identity becomes the norm rather than the exception, the cheap end of this market gets much easier for you to read.
GLP3-R (retatrutide)
Research-use-only material, sold by the vial with batch documentation. Check the certificate of analysis against the batch you receive.
What to know now
- There is no list price. Retatrutide has no approval, so no pharmacy, insurer or manufacturer publishes a number to compare against.
- Cost per milligram is the comparable number. Compare it only at a stated purity and a stated testing standard, or you are comparing nothing.
- Vial size drives the apparent gap. Two suppliers can look far apart on price and be close once you divide by the milligrams.
- A prescription comparison is not a comparison. There is no approved retatrutide product, so a monthly cost borrowed from an approved drug misleads.
- Price is the last check, not the first. Purity, testing and identity decide whether a cost-per-milligram figure means anything at all.
References
- Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023). Triple–hormone-receptor agonist retatrutide for obesity — A phase 2 trial. New England Journal of Medicine, 389(6), 514–526. https://doi.org/10.1056/NEJMoa2301972
- ClinicalTrials.gov. A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Are Overweight (TRIUMPH-1). clinicaltrials.gov retatrutide https://clinicaltrials.gov/search?cond=&term=retatrutide
- U.S. Food and Drug Administration. (2024). Section 503A of the Federal Food, Drug, and Cosmetic Act. https://www.fda.gov/drugs/human-drug-compounding/section-503a-federal-food-drug-and-cosmetic-act
- U.S. Food and Drug Administration. (2013). Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only. FDA Guidance Document. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/distribution-vitro-diagnostic-products-labeled-research-use-only-or-investigational-use-only